Join Dr John Butler, Field Applications Scientist and MSD specialists for an overview of the Meso Scale Discovery Electrochemiluminescence (ECL) Technology.
The seminar will include case studies in the following fields;
- Immunogenicity and Toxicology
- Validated Cytokine Analysis in the Immuno Oncology Field
- Novel Assays of Oncology, Metabolics and Neurodegeneration
- Serology Assays used in Vaccine Development
- Fg/ml sensitivity in Alzheimers
- Assay Development Via MSD Assay Services
- Biomarker Screening in Discovery through MSD Assay Services
Following the seminar, Dr Butler and Nicki Senior, Meso Scale Discovery, will be available to discuss your application areas further. A QuickPlex SQ120 reader will be placed at Alderley Park on a trial basis during April and attendees are invited to run their own measurements with the support of the Field Applications Team.
Founded in 1995, Meso Scale Discovery (MSD) is a global leader in the development, manufacture, and commercialization of innovative assays and instruments for the measurement of molecules in biological samples. MSD’s proprietary MULTI‑ARRAY technology enhances medical research and drug development by enabling researchers to profile many biomarkers simultaneously in a single sample without compromising assay performance. MSD’s technology has been widely adopted by researchers in pharmaceutical companies, government institutions, universities, and clinical laboratories worldwide for its high sensitivity, excellent reproducibility, and wide dynamic range. Throughout its history, MSD has continued to evolve its technology platform to enable researchers to solve complex biological questions and, as the Company looks toward the future, it is expanding into clinical applications and the emerging fields of personalized medicine and companion diagnostics.